Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. According to the American Cancer Society, approximately 14,500 new cases ...

Bio-Path Holdings Inc (NASDAQ:BPTH) reported interim data from Stage 2 of the company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for acute myeloid leukemia (AML).

Please provide your email address to receive an email when new articles are posted on . Researchers at Tisch Cancer Center have created innovative models of acute myeloid leukemia, offering an ...

Abstract available on ASH websiteSAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” ...

Moleculin Biotech ( ($MBRX) ) has issued an announcement. On November 13, 2025, Moleculin Biotech announced that 60% of the target subjects have ...

Details for the Company’s ASH abstracts and oral presentation can be found here: Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the ...

Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry One hundred ...

‒ Voruciclib alone or in combination with venetoclax was generally well tolerated with no significant myelosuppression ‒ – Encouraging preliminary efficacy signal demonstrated with voruciclib alone ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) stock is trading lower on Tuesday after the company issued an update on the SELECT-AML-1 Phase 2 trial. The company announced that it will discontinue ...